Synairgen’s Hopes For Inhaled COVID-19 Therapy Dwindle
Hospital Study Fails
Executive Summary
The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.